NCT03947385: Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: GNA
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have tumors that express a GNAQ/11 hotspot mutation
Exclusions: Patients with known symptomatic brain metastases; Patients with prior treatment of a PKC, MEK, ALK, MET, or ROS1 inhibitor; Patients with MSI-H/dMMR tumors who have not previously received immune checkpoint inhibitors

Comments are closed.

Up ↑